Intellectual Property & Patents

Proprietary AI Healthcare Architecture

Proprietary Technology Assets

LATAMED AI owns certain intellectual property assets relating to its artificial intelligence-enabled healthcare analytics platform, including issued patents and proprietary software acquired pursuant to its Asset Purchase Agreement. The Company’s intellectual property portfolio includes artificial intelligence model architectures, analytical methodologies, disease-specific modeling configurations, software source code, technical documentation, data processing frameworks, and trade secrets and proprietary development materials.

Issued Patents – Venezuela

The Company holds issued patents registered with the Autonomous Service of Intellectual Property (SAPI) in the
Bolivarian Republic of Venezuela.

The Company is authorized to issue 700,000,000 shares of common stock and 300,000,000 shares of preferred stock.As of the most recent public filing, 56,296,895 shares of common stock were issued and outstanding. No shares of preferred stock are currently issued or outstanding.

Geographic Scope of Protection

The Company does not currently hold issued patents in the United States or other jurisdictions. While additional intellectual property filings may be considered in the future, there can be no assurance that patent protection will be obtained outside of Venezuela or that existing patents will provide meaningful competitive protection in international markets.

Trade Secrets & Proprietary Software

In addition to issued patents, the Company's intellectual property includes proprietary software code, model training configurations, structured analytical frameworks, and internal development methodologies. Certain aspects of the platform's architecture rely on trade secret protections rather than patent filings.

The Company may incorporate open-source components into its architecture and intends to manage compliance with applicable licensing requirements through internal review procedures.

Patent issuance does not constitute regulatory approval of medical claims. The Company's artificial intelligence modules remain under development and have not undergone clinical validation or regulatory review in any jurisdiction.

Ready to Transform Healthcare Delivery?

Discover how LATAMED AI’s intelligent healthcare infrastructure can support your organization’s strategic objectives.

Building intelligent healthcare infrastructure for emerging markets through AI-enabled analytics and coordinated care systems.

Platform

Company

Investor Relations

LATAMED AI is a brand name used by Catalyst Crew Technologies Corp. Catalyst Crew Technologies Corp. is a publicly traded company subject to the reporting requirements of the Securities Exchange Act of 1934.